Protective effects of apigenin on LPS-induced endometritis via activating Nrf2 signaling pathway

Peiyue Jiang, Xiaojun Zhu, Yina Zhang, Feifei Zhou, Xiaofu Yang
In: Microbial Pathogenesis · 2018 · vol. 123 , pp. 139–143 · doi:10.1016/j.micpath.2018.06.031 · PMID:29928944 · W2808929048
article OA: closed CC0 ⤵ 3 in-corpus citations
View on OpenAlex View on PubMed View at publisher
⚙ AI-generated summary by claude@2026-06, 2026-06-11 ⓘ

This study investigated apigenin's protective effects against LPS-induced endometritis and found that it activates the Nrf2 signaling pathway to achieve this protection.

One-sentence paraphrase of the abstract; not a substitute for reading it. No clinical advice. How this works

Abstract

Endometritis is a puzzling disease that often associates with severe pelvic pain. In this study, we aimed to detect whether apigenin had protective effect against LPS-induced endometritis, if so, the underlying mechanism was further investigated. Apigenin was administrated 1 h before LPS treatment. The levels of inflammatory cytokines were measured by ELISA. The expression of NF-κB and Nrf2 were detected by Western blot analysis. The results showed that LPS treatment induced severe histological alteration of uterus and this change was attenuated by the treatment of apigenin. Apigenin significantly attenuated LPS-induced MPO activity, MDA content, and inflammatory cytokines TNF-α and IL-1β production. LPS-induced NF-κB activation was suppressed by apigenin. Furthermore, apigenin elevated the expression of Nrf2 and HO-1 in uterine tissues. In conclusion, the present study demonstrated that apigenin protected against LPS-induced endometritis through activation of Nrf2 signaling pathway and inhibition of NF-κB signaling pathway.

My notes (saved in your browser only)

Condition tags

disambig:endometritis

Citation neighborhood (sparse)

Too few in-corpus citations on either side for a chart; here are the lists.

Cited by (4)

References (35)

Cited by (4)

Source provenance

openalex
last seen: 2026-06-10T17:14:06.276822+00:00
License: CC0 · commercial use OK